MCL Literature Feed

This case report describes blastoid MCL presenting as an isolated cecal mass, highlighting an unusual clinical presentation and the need to consider lymphoma in the differential for GI tumors.

This study evaluates the outcomes of Rituximab-Bendamustine (RB) versus the CHASER regimen as induction therapy for transplant-eligible mantle cell lymphoma, informing pre-transplant treatment selection.

This case report describes a hyperacute, aggressive presentation of small cell, non-nodal MCL, highlighting the clinical heterogeneity and challenging prognostic assumptions for this typically indolent subtype.

This case report describes an MCL diagnosis in a patient with mucous membrane pemphigoid, where frontline acalabrutinib and rituximab resolved both conditions, suggesting a paraneoplastic link.

This case report demonstrates that MCL can rarely cause membranous nephropathy, a severe renal complication that can be fully resolved by successfully treating the underlying lymphoma with chemotherapy.

This 20-year Taiwanese retrospective study confirms that frontline rituximab, intensive chemotherapy, and autologous transplant are associated with improved survival, validating these established strategies in a real-world Asian cohort.

In newly diagnosed MCL, PET/CT-based bone marrow assessment has greater prognostic value than biopsy and is incorporated into a new MCL-PET-I index for improved risk stratification.

This review highlights that TP53-mutated MCL represents a distinct high-risk entity with poor outcomes to chemoimmunotherapy, underscoring the urgent need for novel, non-chemotherapy frontline approaches in these patients.

Reviewing the TRIANGLE trial, this paper argues that adding ibrutinib to frontline induction makes omitting autologous stem cell transplant consolidation a non-inferior, less toxic option for young patients.

This review synthesizes the evolution of BTK-targeted therapies, from covalent inhibitors to non-covalent agents and degraders, outlining current treatment paradigms and future combination strategies for frontline and relapsed MCL.

This case report demonstrates that MCL can cause severe renal failure via both direct infiltration and paraneoplastic glomerulonephritis, underscoring the need for kidney biopsy in unexplained nephropathy.

Analysis of European MCL Network trial data shows specific gene mutations predict patient outcomes, providing a genetic basis for risk stratification to guide therapy selection beyond clinical scores.

Long-term follow-up after autologous stem cell transplant in MCL is critical for detecting late relapses and managing treatment-related toxicities, guiding post-transplant surveillance strategies.

Bendamustine-induced lymphopenia in frontline MCL resolves by 12 months, suggesting a minimum 9-month wait before leukapheresis for CAR-T therapy to ensure sufficient lymphocyte collection.

This review highlights that excellent outcomes with modern frontline chemo-immunotherapy plus BTK inhibitors are challenging the traditional role of autologous transplant consolidation in mantle cell lymphoma.

In a small retrospective study of nine untreated aggressive MCL patients, adding a BTKi to chemoimmunotherapy achieved a 100% objective response rate with manageable toxicity, suggesting a promising frontline strategy.

This retrospective study confirms poor outcomes for blastoid MCL with chemo-immunotherapy, advocating for upfront 2nd/3rd generation BTKi-based therapies to improve survival in this high-risk population.

This case of cardiac MCL with a mobile tumor highlights the risk of fatal pulmonary embolism post-chemotherapy, suggesting a potential role for pre-treatment surgical intervention in this rare presentation.

The frontline, chemotherapy-free triplet of acalabrutinib, venetoclax, and rituximab achieved 100% ORR and high MRD negativity, establishing a potent, time-limited option despite significant COVID-19 toxicity.

In older, frontline MCL patients, adding bortezomib to BR induction or lenalidomide to rituximab maintenance did not improve PFS, confirming BR-R as a highly effective standard.

This first-reported case of sphenoid sinus MCL causing acute bilateral blindness demonstrates that prompt chemo-surgical intervention can partially reverse vision loss, highlighting a rare but critical CNS presentation.

This case report documents a rare presentation of mantle cell lymphoma as complete heart block from cardiac metastasis, highlighting a critical differential diagnosis for unexplained conduction abnormalities.

A high monocyte-to-platelet ratio (MPR ≥ 3) at diagnosis is a novel, independent prognostic biomarker for inferior progression-free survival in transplant-ineligible mantle cell lymphoma patients.

This large, real-world study confirms cytarabine-based induction provides the longest front-line PFS (68 months), while second-line chemotherapy outcomes are poor (14 months PFS), highlighting the need for novel agents.

This case report details a rare MCL presentation as intestinal intussusception, requiring surgical resection for diagnosis and initial management prior to systemic chemotherapy in a young patient.

This review summarizes how molecular profiling (e.g., TP53) and MRD are reshaping MCL therapy by integrating novel agents into frontline care, personalizing treatment, and improving high-risk patient outcomes.

Analysis of the FIL MCL0208 trial shows that stem cell collection and subsequent hematological recovery are feasible and safe in young, fit MCL patients undergoing frontline autologous transplant consolidation.

For transplant-eligible MCL, substituting rituximab with obinutuzumab in chemo-immunotherapy induction and maintenance significantly improved MRD negativity, 5-year progression-free survival (83% vs 67%), and overall survival.

This commentary evaluates rituximab's evolving role in MCL, questioning its necessity in modern chemo-free regimens and its place alongside novel targeted agents.

This large Chinese retrospective study of blastoid/pleomorphic MCL links progression of disease within 12 months (POD12) to a distinct mutation profile (TP53, SMARCA4) and poor prognosis.